Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+advanced, unresectable or metastatic G/GEJ adenocarcinoma

被引：0

作者：

Janjigian, Y. Y. ^{[1
]}

Kawazoe, A. ^{[2
]}

Bai, Y. ^{[3
]}

Xu, J. ^{[4
]}

Lonardi, S. ^{[5
]}

Metges, J-P. ^{[6
]}

Weber, P. E. Yanez ^{[7
]}

Wyrwicz, L. S. ^{[8
]}

Shen, L. ^{[9
]}

Ostapenko, Y. V. ^{[10
]}

Bilici, M. ^{[11
]}

Chung, H. C. ^{[12
]}

Shitara, K. ^{[13
]}

Mahave, M. ^{[14
]}

Van Cutsem, E. ^{[15
]}

Tabernero, J. ^{[16
]}

Xu, L. ^{[17
]}

Sharan, K. ^{[17
]}

Bhagia, P. ^{[17
]}

Rha, S. Y. ^{[12
]}

机构：

[1] MSKCC Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA

[2] Natl Canc Ctr Hosp East, Gastroenterol & Gastrointestinal Oncol Dept, Kashiwa, Chiba, Japan

[3] Harbin Med Univ, Harbin, Peoples R China

[4] Beijing 302 Hosp, Chinese PLA Gen Hosp, Med Ctr 5, Gastrointestinal Dept, Beijing, Peoples R China

[5] IOV Ist Oncol Veneto IRCCS, Dept Oncol, Padua, Italy

[6] Univ Hosp Brest, Dept Oncol, Brest, France

[7] Clin Alemana Temuco SA, Dept Oncol, Temuco, Chile

[8] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Radiotherapy & Oncol, Warsaw, Poland

[9] Peking Univ Canc Hosp & Inst, GI Oncol Dept, Beijing, Peoples R China

[10] Minist Hlth Ukraine, Natl Canc Inst, Surg Dept, Kiev, Ukraine

[11] Ataturk Univ, Fac Med, Med Oncol Dept, Erzurum, Turkiye

[12] Yonsei Univ, Coll Med, Med Oncol Dept, Seoul, South Korea

[13] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan

[14] FALP Fdn Arturo Lopez Perez, Inst Oncol, Providencia, Chile

[15] UZ Leuven, Univ Hosp Leuven, Digest Oncol Dept, Campus Gasthuisberg, Leuven, Belgium

[16] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain

[17] Merck & Co Inc, Oncol Late Dev Dept, Rahway, NJ USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1466

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1400O

引用

页码：S877 / S878

页数：2